Compositions and methods relating to nucleic acid-protein complexes
View Patent ↗Provided are methods and compositions relating to conjugation of nucleic acids and proteins of interest under conditions that maintain protein activity. The nucleic acid-protein conjugates may be used in nucleic acid nanostructures such as those generated using DNA origami methods.
1. A method comprising
reacting a nucleic acid conjugated to an amino acid sequence comprising a terminal glycine (G) residue with a protein comprising a terminal amino acid sequence of LPXTGX′ n (SEQ ID NO: 2), wherein X is any amino acid, X′ n is a string of independently selected amino acids of length n, and n is a number or any range of numbers from 1 to 100, in the presence of a sortase enzyme to form a complex comprising the nucleic acid covalently conjugated to the protein through an amino acid linker having an amino acid sequence of LPXTGGG (SEQ ID NO: 9), wherein X is any amino acid,
wherein the nucleic acid conjugated to an amino acid sequence is incorporated in a nucleic acid nanostructure.
2. The method of claim 1 , wherein the sortase enzyme and the protein comprising a terminal amino acid sequence of LPXTGX′ n (SEQ ID NO: 2) each comprises a His-tag.
3. The method of claim 1 , wherein the terminal amino acid sequence is LPETGX′ n (SEQ ID NO: 3), wherein X′ n is a string of amino acids of length n and n is a number or any range of numbers from 1 to 100, and wherein the amino acid sequence of the amino acid linker is LPETGGG (SEQ ID NO: 5).
4. The method of claim 1 , wherein n is a number greater than 1, and less than or equal to 100.
5. The method of claim 1 , wherein the nucleic acid conjugated to an amino acid sequence comprising a terminal glycine (G) residue is formed by a bio-orthogonal copper catalyzed click chemistry reaction.
6. The method of claim 5 , wherein the bio-orthogonal copper catalyzed click chemistry reaction forms a nucleic acid intermediate comprising a nucleic acid conjugated to one or more glycine (G) residues and a TEV target amino acid sequence.
7. The method of claim 6 , wherein the nucleic acid intermediate is reacted with TEV protease.
8. The method of claim 7 , wherein the TEV protease is conjugated to a His-tag.
9. The method of claim 2 , wherein the His-tag is an amino acid sequence of six histidine residues (SEQ ID NO: 6).
10. The method of claim 1 , the protein in the formed complex has a specific activity that is at least 75% of the specific activity of the protein in an unconjugated and unmanipulated form.
11. The method of claim 1 , the protein in the formed complex has a specific activity that is at least 80% of the specific activity of the protein in an unconjugated and unmanipulated form.
12. The method of claim 1 , the protein in the formed complex has a specific activity that is at least 90% of the specific activity of the protein in an unconjugated and unmanipulated form.
13. The method of claim 1 , the protein in the formed complex has a specific activity that is about 100% of the specific activity of the protein in an unconjugated and unmanipulated form.